Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
VENUS REMEDIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VENUS REMEDIES Mar-23 |
TEVA PHARMA Dec-13 |
VENUS REMEDIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 379 | 3,486 | - | |
Low | Rs | 145 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 415.5 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 19.9 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 44.0 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.40 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 344.3 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 13.37 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.6 | 1.6 | 38.7% | |
Avg P/E ratio | x | 13.2 | 26.1 | 50.6% | |
P/CF ratio (eoy) | x | 5.9 | 11.4 | 52.4% | |
Price / Book Value ratio | x | 0.8 | 1.5 | 51.9% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 3,501 | 2,761,843 | 0.1% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 570 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,555 | 1,696,422 | 0.3% | |
Other income | Rs m | 103 | 0 | - | |
Total revenues | Rs m | 5,658 | 1,696,422 | 0.3% | |
Gross profit | Rs m | 602 | 464,566 | 0.1% | |
Depreciation | Rs m | 323 | 137,123 | 0.2% | |
Interest | Rs m | 3 | 33,320 | 0.0% | |
Profit before tax | Rs m | 379 | 294,122 | 0.1% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 114 | -3,591 | -3.2% | |
Profit after tax | Rs m | 266 | 105,974 | 0.3% | |
Gross profit margin | % | 10.8 | 27.4 | 39.6% | |
Effective tax rate | % | 30.0 | -1.2 | -2,454.1% | |
Net profit margin | % | 4.8 | 6.2 | 76.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,230 | 1,145,757 | 0.3% | |
Current liabilities | Rs m | 826 | 999,197 | 0.1% | |
Net working cap to sales | % | 43.3 | 8.6 | 500.9% | |
Current ratio | x | 3.9 | 1.1 | 341.1% | |
Inventory Days | Days | 37 | 91 | 40.7% | |
Debtors Days | Days | 504 | 96 | 525.2% | |
Net fixed assets | Rs m | 2,781 | 554,089 | 0.5% | |
Share capital | Rs m | 134 | 4,176 | 3.2% | |
Net worth | Rs m | 4,603 | 1,884,403 | 0.2% | |
Long term debt | Rs m | 387 | 867,418 | 0.0% | |
Total assets | Rs m | 6,011 | 3,876,868 | 0.2% | |
Interest coverage | x | 130.0 | 9.8 | 1,323.0% | |
Debt to equity ratio | x | 0.1 | 0.5 | 18.3% | |
Sales to assets ratio | x | 0.9 | 0.4 | 211.2% | |
Return on assets | % | 4.5 | 3.6 | 124.4% | |
Return on equity | % | 5.8 | 5.6 | 102.6% | |
Return on capital | % | 7.7 | 4.9 | 155.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 366 | 270,322 | 0.1% | |
From Investments | Rs m | -508 | -95,786 | 0.5% | |
From Financial Activity | Rs m | -6 | -324,269 | 0.0% | |
Net Cashflow | Rs m | -220 | -149,733 | 0.1% |
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare VENUS REMEDIES With: GANGA PHARMACEUTICALS BH.IMMUN&BIO WOCKHARDT CONCORD DRUGS JFL LIFE SCIENCES LTD.
It was indeed a volatile trading session for Indian share markets yesterday.